Ignacio Melero

机构：Churchill Hospital, Nuffield Orthopaedic Centre, University of Oxford, Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Universidad de Navarra · ORCID：0000-0002-1360-348X

发表论文 1075 篇 · 总被引 52545 次 · h-index 110

代表论文

• Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors (2026 · Journal of Hematology & Oncology · 被引 1)
• CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells (2026 · The EMBO Journal)
• Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors (2026 · Cancer Research)
• TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment (2026 · The Journal of Experimental Medicine)
• Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial (2026 · Clinical Cancer Research)
• Additional file 1 of Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors (2026 · Figshare)